Yingwei Chang, Lijun Yao, Shiquan Liu, Mingyang Nie
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The use of MR contrast in nonneoplastic disease of the brain.
10.1097/00002142-199500730-00004 · 1995
Clinical safety of gadoteridol, representative of the macrocyclic class of gadolinium-based contrast agents.
10.1002/jmri.26957 · 2020
Basic MR relaxation mechanisms and contrast agent design.
10.1002/jmri.24787 · 2015
Design of gadoteridol-loaded cationic liposomal adjuvant CAF01 for MRI of lung deposition of intrapulmonary administered particles.
10.1021/acs.molpharmaceut.9b00908 · 2019
Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.
10.2214/ajr.10.5992 · 2011
Quantitatively relating magnetic resonance T(1) and T(2) to glycosaminoglycan and collagen concentrations mediated by penetrated contrast agents and biomacromolecule-bound water.
10.1093/rb/rbad035 · 2023
Prospective imaging trial assessing gadoteridol retention in the deep brain nuclei of women undergoing breast MRI.
10.1016/j.acra.2020.01.007 · 2020
Gadolinium-based contrast agent biodistribution and speciation in rats.
10.1148/radiol.230984 · 2023
Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-Associated reports in the FDA Adverse Event Reporting System (FAERS).
10.1016/j.jaip.2020.09.021 · 2021
The medical dictionary for regulatory activities (MedDRA).
10.2165/00002018-199920020-00002 · 1999
Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database.
10.1038/s41598-024-67209-0 · 2024
The reporting odds ratio and its advantages over the proportional reporting ratio.
10.1002/pds.1001 · 2004
Data mining of the public version of the FDA adverse event reporting system.
10.7150/ijms.6048 · 2013
Adverse events related to off-label drugs using spontaneous adverse event reporting systems.
10.2147/tcrm.s321789 · 2021
Ginkgo biloba extract safety: insights from a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.
10.1016/j.jep.2024.119010 · 2025
Modified generalized Weibull distribution: theory and applications.
10.1038/s41598-023-38942-9 · 2023
Parametric regression model for survival data: Weibull regression model as an example.
10.21037/atm.2016.08.45 · 2016
Recent developments and future perspectives in magnetic resonance imaging and computed tomography contrast media.
10.1097/rli.0000000000001180 · 2026
Consensus Guidelines of the French Society of Neuroradiology (SFNR) on the use of Gadolinium-Based Contrast agents (GBCAs) and related MRI protocols in Neuroradiology.
10.1016/j.neurad.2020.05.008 · 2020
Contrast-enhanced cardiac magnetic resonance imaging with a manganese-based alternative to gadolinium for tissue characterization of acute myocardial infarction.
10.1161/jaha.122.026923 · 2023
Clinical safety of gadobutrol: review of over 25 years of use exceeding 100 million administrations.
10.1097/rli.0000000000001072 · 2024
Safety concerns of maternal antiseizure medications exposure on perinatal and offspring outcomes: a disproportionality analysis based on FDA adverse event reporting system.
10.1007/s00415-025-13172-3 · 2025
Differences in hypersensitivity reactions and gadolinium deposition disease/symptoms associated with gadolinium exposure to gadolinium-based contrast agents: new insights based on global databases VigiBase, FAERS, and IQVIA-MIDAS.
10.1186/s12916-024-03537-2 · 2024
The reporting frequency of skin lesions in contrast media-induced chemical hypersensitivity.
2019
Assessment of first-time and repeated acute adverse reactions to gadolinium-based contrast agents in MRI: a retrospective study.
10.1016/j.ejrad.2024.111504 · 2024
Relationship between patient-friendly audiovisual systems and MRI contrast agent to adverse reactions.
10.1002/jmri.28951 · 2024
Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis.
10.1001/jamainternmed.2019.5284 · 2020
A mast-cell-specific receptor mediates Iopamidol induced immediate IgE-independent anaphylactoid reactions.
10.1016/j.intimp.2019.105800 · 2019
MRGPRX2 mediates immediate-type pseudo-allergic reactions induced by iodine-containing iohexol.
10.1016/j.biopha.2021.111323 · 2021
Inhibitory effect of daphnetin on the C48/80-induced pseudo-allergic reaction.
10.1016/j.intimp.2023.110874 · 2023
Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention.
2014
Road less traveled: drug hypersensitivity to fluoroquinolones, vancomycin, tetracyclines, and macrolides.
10.1007/s12016-021-08919-5 · 2022
Anti-pseudo-allergy effect of isoliquiritigenin is MRGPRX2-dependent.
10.1016/j.imlet.2018.04.004 · 2018
Auricular vagal nerve stimulation inhibited central nerve growth factor/tropomyosin receptor kinase A/Phospholipase C-Gamma signaling pathway in functional dyspepsia model rats with gastric hypersensitivity.
10.1016/j.neurom.2023.01.007 · 2024
Gadoteridol-enhanced MRI of the breast: can contrast agent injection rate impact background parenchymal enhancement?
10.1177/02841851211034038 · 2022
Navigating nephrotoxic waters: a comprehensive overview of contrast-induced acute kidney injury prevention.
10.4329/wjr.v16.i6.168 · 2024
Preventing allergic reactions to gadolinium-based contrast agents.
10.1097/rmr.0000000000000106 · 2016
Sexual dimorphism in drug metabolism and pharmacokinetics.
10.2174/1389200220666191021094906 · 2019
Sex hormones and epigenetic dysregulation in autoimmune disease.
10.1016/j.coi.2025.102595 · 2025
No additional external references are available.
